应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
IVBIY Innovent Biologics Inc.
休市中 12-05 09:30:04 EST 延时
资讯
新帖
简况
2025 ACR | 信达生物综合管线的多项临床前研究数据亮相
美通社 · 11-05
2025 ACR | 信达生物综合管线的多项临床前研究数据亮相
降糖减重双优效，玛仕度肽头对头司美格鲁肽
美通社 · 10-27
降糖减重双优效，玛仕度肽头对头司美格鲁肽
信达生物合作伙伴 Ollin 公布眼科双抗IBI324（抗VEGF/ANG-2双特异性抗体）临床进展
美通社 · 09-18
信达生物合作伙伴 Ollin 公布眼科双抗IBI324（抗VEGF/ANG-2双特异性抗体）临床进展
信达生物将在第34届欧洲皮肤病学会（EADV）2025年会公布综合管线免疫领域多项研究数据
美通社 · 09-16
信达生物将在第34届欧洲皮肤病学会（EADV）2025年会公布综合管线免疫领域多项研究数据
信达生物宣布IBI128（替古索司他片，XOI）痛风临床II期研究结果于亚太风湿病协会联盟大会（APLAR）公布
美通社 · 09-08
信达生物宣布IBI128（替古索司他片，XOI）痛风临床II期研究结果于亚太风湿病协会联盟大会（APLAR）公布
头对头帕博利珠单抗，信达生物IBI363（PD-1/IL-2α-bias双特异性抗体融合蛋白）首个关键注册临床研究完成首例受试者给药，用于治疗黑色素瘤
美通社 · 03-03
头对头帕博利珠单抗，信达生物IBI363（PD-1/IL-2α-bias双特异性抗体融合蛋白）首个关键注册临床研究完成首例受试者给药，用于治疗黑色素瘤
信达生物宣布首个中国研发的CTLA-4单抗伊匹木单抗注射液联合信迪利单抗用于结肠癌新辅助治疗的新药上市申请获受理并纳入优先审评
美通社 · 02-24
信达生物宣布首个中国研发的CTLA-4单抗伊匹木单抗注射液联合信迪利单抗用于结肠癌新辅助治疗的新药上市申请获受理并纳入优先审评
信达生物IBI363 (PD-1/IL-2α-bias双特异性抗体融合蛋白) 再获美国FDA快速通道资格认定，治疗鳞状非小细胞肺癌
美通社 · 02-17
信达生物IBI363 (PD-1/IL-2α-bias双特异性抗体融合蛋白) 再获美国FDA快速通道资格认定，治疗鳞状非小细胞肺癌
JPM 2025 ｜ 聚势向前：信达生物迈进双极驱动和全球创新发展新时期
美通社 · 01-17
JPM 2025 ｜ 聚势向前：信达生物迈进双极驱动和全球创新发展新时期
信达生物与奥赛康药业宣布第三代EGFR TKI 肺癌靶向药物奥壹新®（利厄替尼片）获批上市
美通社 · 01-17
信达生物与奥赛康药业宣布第三代EGFR TKI 肺癌靶向药物奥壹新®（利厄替尼片）获批上市
信达生物IBI343 (CLDN 18.2 ADC) 获国家药品监督管理局纳入突破性治疗药物品种，治疗晚期胰腺导管腺癌患者
美通社 · 01-16
信达生物IBI343 (CLDN 18.2 ADC) 获国家药品监督管理局纳入突破性治疗药物品种，治疗晚期胰腺导管腺癌患者
信达生物将出席第43届摩根大通全球医疗健康年会并发表演讲
美通社 · 01-06
信达生物将出席第43届摩根大通全球医疗健康年会并发表演讲
信达生物宣布ROS1抑制剂达伯乐®（己二酸他雷替尼胶囊）获批第二项适应症，用于全线治疗 ROS1 阳性肺癌
美通社 · 01-03
信达生物宣布ROS1抑制剂达伯乐®（己二酸他雷替尼胶囊）获批第二项适应症，用于全线治疗 ROS1 阳性肺癌
信达生物宣布ROS1抑制剂达伯乐®（己二酸他雷替尼胶囊）获国家药品监督管理局批准上市
美通社 · 2024-12-20
信达生物宣布ROS1抑制剂达伯乐®（己二酸他雷替尼胶囊）获国家药品监督管理局批准上市
信达生物与礼来制药深化肿瘤领域合作，达成捷帕力®（匹妥布替尼片）中国大陆商业化协议
美通社 · 2024-12-16
信达生物与礼来制药深化肿瘤领域合作，达成捷帕力®（匹妥布替尼片）中国大陆商业化协议
2024 ESMO Asia | 信达生物口头报告创新型抗CLDN18.2 ADC（IBI343）治疗晚期胰腺癌的I期临床研究数据更新
美通社 · 2024-12-09
2024 ESMO Asia | 信达生物口头报告创新型抗CLDN18.2 ADC（IBI343）治疗晚期胰腺癌的I期临床研究数据更新
信达生物宣布信必乐®（托莱西单抗注射液）新药、耐立克®（奥雷巴替尼）新增适应症成功纳入2024年版国家医保药品目录
美通社 · 2024-11-28
信达生物宣布信必乐®（托莱西单抗注射液）新药、耐立克®（奥雷巴替尼）新增适应症成功纳入2024年版国家医保药品目录
信达生物将在ESMO Asia 2024年会上公布IBI343（CLDN18.2 ADC）等多项创新管线更新临床数据
美通社 · 2024-11-25
信达生物将在ESMO Asia 2024年会上公布IBI343（CLDN18.2 ADC）等多项创新管线更新临床数据
信达生物宣布匹康奇拜单抗（IL-23p19抗体）治疗溃疡性结肠炎的II期临床研究达成主要终点
美通社 · 2024-10-17
信达生物宣布匹康奇拜单抗（IL-23p19抗体）治疗溃疡性结肠炎的II期临床研究达成主要终点
信达生物与奥赛康药业达成第三代EGFR TKI 肺癌靶向药物利厄替尼片（奥壹新®）的战略合作
美通社 · 2024-10-08
信达生物与奥赛康药业达成第三代EGFR TKI 肺癌靶向药物利厄替尼片（奥壹新®）的战略合作
加载更多
公司概况
公司名称：
Innovent Biologics Inc.
所属市场：
PINK LIMITED
上市日期：
--
主营业务：
发行价格：
--
{"stockData":{"symbol":"IVBIY","market":"US","secType":"STK","nameCN":"Innovent Biologics Inc.","latestPrice":45.184,"timestamp":1764945004741,"preClose":45.184,"halted":0,"volume":29,"delay":15,"floatShares":407000000,"shares":407000000,"eps":-0.00822,"marketStatus":"休市中","change":0,"latestTime":"12-05 09:30:04 EST 延时","open":45.184,"high":45.184,"low":45.184,"amount":1444.78,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.00822,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1765184400000},"marketStatusCode":7,"adr":0,"adrRate":4,"exchange":"PINK LIMITED","adjPreClose":45.184,"volumeRatio":0.6872046056926607},"requestUrl":"/m/hq/s/IVBIY","defaultTab":"news","newsList":[{"id":"2581717853","title":"2025 ACR | 信达生物综合管线的多项临床前研究数据亮相","url":"https://stock-news.laohu8.com/highlight/detail?id=2581717853","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581717853?lang=zh_cn&edition=full","pubTime":"2025-11-05 08:00","pubTimestamp":1762300800,"startTime":"0","endTime":"0","summary":"美国旧金山和中国苏州2025年11月5日 /美通社/ --信达生物制药集团，一家致力于研发、生产和销售肿瘤、自身免疫、代谢及心血管、眼科等重大疾病领域创新药物的生物制药公司，今日宣布，2025年美国风湿病学会年会上综合管线的多项最新研究数据亮相，包括IBI3011和IBI3034的临床前研究。本次大会于2025年10月24-29日在美国芝加哥召开。截至目前，信达生物患者援助项目已惠及20余万普通患者，药物捐赠总价值36亿元人民币。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4814968_ZH14968_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["ACR","BK1589","BK4110","LU2242644610.SGD","BK1583","BK4139","LU2097828474.EUR","01801","LU2097828631.EUR","LU2097828714.EUR","BK1161","LU2097828557.USD","LU2097828805.USD","IVBIY","LU0455707207.USD","LU0502904849.HKD","LU2488822045.USD","LU2328871848.SGD","LU1969619763.USD"],"gpt_icon":0},{"id":"2578732666","title":"降糖减重双优效，玛仕度肽头对头司美格鲁肽","url":"https://stock-news.laohu8.com/highlight/detail?id=2578732666","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578732666?lang=zh_cn&edition=full","pubTime":"2025-10-27 08:00","pubTimestamp":1761523200,"startTime":"0","endTime":"0","summary":"作为全球首个上市的GCG/GLP-1双受体激动剂，玛仕度肽最新III期临床研究证明，在兼顾降糖和减重双重效果方面，其疗效优于司美格鲁肽，并带来更明显的多重代谢改善，安全性良好，为糖尿病合并肥胖患者的代谢管理提供了新的药物选择。此次玛仕度肽头对头司美格鲁肽的DREAMS-3研究结果更进一步证明玛仕度肽相较司美格鲁肽在2型糖尿病合并肥胖患者中的减重和降糖优势。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4806958_ZH06958_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU2488822045.USD","OXM","LU2242644610.SGD","LU2097828557.USD","BK1161","LU1969619763.USD","BK1583","LU0502904849.HKD","BK1589","IVBIY","BK4202","BMI","LU0455707207.USD","LU2097828474.EUR","LU2097828631.EUR","LU2328871848.SGD","LU2097828805.USD","01801","LU2097828714.EUR","BK4139","BK4157"],"gpt_icon":0},{"id":"2568440013","title":"信达生物合作伙伴 Ollin 公布眼科双抗IBI324（抗VEGF/ANG-2双特异性抗体）临床进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2568440013","media":"美通社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568440013?lang=zh_cn&edition=full","pubTime":"2025-09-18 12:00","pubTimestamp":1758168000,"startTime":"0","endTime":"0","summary":"预计该研究的初步结果将于 2026 年第一季度公布。作为新一代 VEGF/Ang2 双特异性抗体，OLN324有望在解剖学治疗结局和疗效持久性方面优于法瑞西单抗等现有标准治疗药物。信达生物将继续与 Ollin 保持协同，加快 OLN324 的研发进程，推动这一急需的治疗方案在全球范围内上市。截至目前，信达生物患者援助项目已惠及17余万普通患者，药物捐赠总价值34亿元人民币。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4775625_ZH75625_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["IVBIY","LU2328871848.SGD","LU2488822045.USD","LU0455707207.USD","LU0502904849.HKD","BK1589","01801","LU2097828714.EUR","LU2097828631.EUR","LU2097828805.USD","BK1161","LU1969619763.USD","LU2097828474.EUR","LU2242644610.SGD","LU2097828557.USD","BK4139","BK1583"],"gpt_icon":0},{"id":"2567770701","title":"信达生物将在第34届欧洲皮肤病学会（EADV）2025年会公布综合管线免疫领域多项研究数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2567770701","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2567770701?lang=zh_cn&edition=full","pubTime":"2025-09-16 09:00","pubTimestamp":1757984400,"startTime":"0","endTime":"0","summary":"2025年9月16日美国旧金山和中国苏州 /美通社/ -- 信达生物制药集团，一家致力于研发、生产和销售肿瘤、自身免疫、代谢及心血管、眼科等重大疾病领域创新药物的生物制药公司，今日宣布，将在2025年欧洲皮肤病学会年会上公布综合管线的多项最新研究数据，包括匹康奇拜单抗的临床II期及III期研究事后分析，IBI3013和IAR129的临床前研究。截至目前，信达生物患者援助项目已惠及17余万普通患者，药物捐赠总价值34亿元人民币。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4773327_ZH73327_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU1969619763.USD","LU2097828714.EUR","BK1583","BK4139","LU0502904849.HKD","LU2097828474.EUR","IVBIY","LU2097828631.EUR","LU2097828805.USD","LU2328871848.SGD","LU2488822045.USD","BK1589","01801","LU2242644610.SGD","LU2097828557.USD","BK1161","LU0455707207.USD","CVM"],"gpt_icon":0},{"id":"2566300156","title":"信达生物宣布IBI128（替古索司他片，XOI）痛风临床II期研究结果于亚太风湿病协会联盟大会（APLAR）公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2566300156","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566300156?lang=zh_cn&edition=full","pubTime":"2025-09-08 08:30","pubTimestamp":1757291400,"startTime":"0","endTime":"0","summary":"美国旧金山和中国苏州2025年9月8日 /美通社/ -- 信达生物制药集团，一家致力于研发、生产和销售肿瘤、自身免疫、代谢及心血管、眼科等重大疾病领域创新药物的生物制药公司宣布：黄嘌呤氧化酶抑制剂替古索司他片在中国痛风患者中的II期临床研究的主要结果在2025年亚太风湿病协会联盟大会发表。基于该积极结果，信达生物计划于2025年下半年启动替古索司他片中国注册临床III期研究。替古索司他片安全性良好。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4766503_ZH66503_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["01801","LU2097828557.USD","LU2328871848.SGD","LU2488822045.USD","BK1583","IVBIY","LU0502904849.HKD","LU0455707207.USD","LU2097828714.EUR","BK1161","LU1969619763.USD","LU2097828631.EUR","LU2242644610.SGD","BK1589","LU2097828805.USD","LU2097828474.EUR","BK4139"],"gpt_icon":0},{"id":"2516452525","title":"头对头帕博利珠单抗，信达生物IBI363（PD-1/IL-2α-bias双特异性抗体融合蛋白）首个关键注册临床研究完成首例受试者给药，用于治疗黑色素瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=2516452525","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516452525?lang=zh_cn&edition=full","pubTime":"2025-03-03 08:00","pubTimestamp":1740960000,"startTime":"0","endTime":"0","summary":"目前，IBI363已开出首个关键注册临床研究，用于治疗未经免疫治疗的粘膜型和肢端型黑色素瘤。另外，IBI363已获美国FDA两项快速通道资格认定，分别用于治疗鳞状非小细胞肺癌和黑色素瘤。截至目前，信达生物患者援助项目已惠及20余万普通患者，药物捐赠总","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4631081_ZH31081_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU2488822045.USD","BK4139","LU1169589451.USD","PD","BK1161","LU1169590202.USD","IVBIY","LU1969619763.USD","LU2328871848.SGD","BK4023","BK1583","BK1589","01801"],"gpt_icon":0},{"id":"2513976262","title":"信达生物宣布首个中国研发的CTLA-4单抗伊匹木单抗注射液联合信迪利单抗用于结肠癌新辅助治疗的新药上市申请获受理并纳入优先审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2513976262","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513976262?lang=zh_cn&edition=full","pubTime":"2025-02-24 07:52","pubTimestamp":1740354720,"startTime":"0","endTime":"0","summary":"伊匹木单抗是首个递交NDA的中国研发的CTLA-4单抗，同时，这也是信迪利单抗奠定其肿瘤免疫治疗领先品牌的又一里程碑。研究旨在评估伊匹木单抗联合信迪利单抗新辅助治疗可切除的MSI-H/dMMR结肠癌对比直接根治性手术的有效性和安全性。伊匹木单抗联合信迪利单抗组与信迪利单抗单药组术后病理淋巴结阳性率分别为3.9%与15.9%。伊匹木单抗联合信迪利单抗用于可切除的MSI-H/dMMR结肠癌患者的新辅助治疗的NDA在NMPA优先审评中。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4625139_ZH25139_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4017","BK4008","ALK","BK1589","LU2328871848.SGD","BK1161","BK1583","BK4139","CDE","01801","LU1969619763.USD","LU2488822045.USD","PP","BK4500","IVBIY","BK4588","BK4585"],"gpt_icon":0},{"id":"2512966214","title":"信达生物IBI363 (PD-1/IL-2α-bias双特异性抗体融合蛋白) 再获美国FDA快速通道资格认定，治疗鳞状非小细胞肺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2512966214","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512966214?lang=zh_cn&edition=full","pubTime":"2025-02-17 08:00","pubTimestamp":1739750400,"startTime":"0","endTime":"0","summary":"旧金山和中国苏州2025年2月17日 /美通社/ -- 信达生物制药集团，一家致力于研发、生产和销售肿瘤、自身免疫、代谢、眼科等重大疾病领域创新药物的生物制药公司，宣布其PD-1/IL-2α-bias双特异性抗体融合蛋白IBI363获得美国食品和药物监督管理局授予快速通道资格，拟定适应症为抗PD-1免疫检查点抑制剂及含铂化疗治疗后进展的局部晚期或转移性鳞状非小细胞肺癌。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4620398_ZH20398_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["PD","LU1169589451.USD","BK1589","BK4139","01801","LU1969619763.USD","BK1161","LU2488822045.USD","BK4023","IVBIY","LU1169590202.USD","LU2328871848.SGD","BK1583"],"gpt_icon":0},{"id":"2504978214","title":"JPM 2025 ｜ 聚势向前：信达生物迈进双极驱动和全球创新发展新时期","url":"https://stock-news.laohu8.com/highlight/detail?id=2504978214","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2504978214?lang=zh_cn&edition=full","pubTime":"2025-01-17 08:18","pubTimestamp":1737073080,"startTime":"0","endTime":"0","summary":"成立13年，信达生物快速成长成为一家中国领先的生物制药企业。展望未来，信达生物战略清晰、稳步落地，2025年将是迈入双轮驱动和全球创新发展新时期的重要一年，业务聚势向前、创新力求突破，公司正朝着“成为国际一流的生物制药公司”的愿景稳步迈进。2025年公司有7款药物计划递交新药上市申请或关键临床进行中，7款创新管线计划启动关键注册临床，为公司快速增长持续提供强劲动力。信达生物在不断自","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4597983_ZH97983_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["IE00B3S45H60.SGD","LU2023250504.SGD","IE00BWXC8680.SGD","LU0238689110.USD","LU1974910355.USD","IE00BDRTCR15.USD","IVBIY","BK1589","LU0048584097.USD","LU0106831901.USD","LU0215105999.USD","LU0787776722.HKD","BK4585","LU1917777945.USD","LU0320765646.SGD","LU2488822045.USD","LU0208291251.USD","LU2242649171.HKD","LU2237443465.HKD","LU0170899867.USD","BK1161","LU2237443895.HKD","IE00BKDWB100.SGD","LU0211327993.USD","LU0976567544.SGD","IE00B775SV38.USD","BK4566","LU0211331839.USD","LU0683600562.USD","BK4207","LU0310799852.SGD","01801","IE00BLSP4452.SGD","IE000M9KFDE8.USD","LU1261432733.SGD","LU2264538146.SGD","IE00B1XK9C88.USD","LU0251132253.USD","LU2357305700.SGD","LU2237443978.SGD","BK4550","IE00BHPRN162.USD","BK4588","LU1244550577.SGD","IE0034235295.USD","LU1119994496.HKD","IE00BJTD4N35.SGD","LU2505996509.AUD","LU0417517546.SGD","LU0320765489.SGD"],"gpt_icon":0},{"id":"2504212978","title":"信达生物与奥赛康药业宣布第三代EGFR TKI 肺癌靶向药物奥壹新®（利厄替尼片）获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2504212978","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2504212978?lang=zh_cn&edition=full","pubTime":"2025-01-17 08:00","pubTimestamp":1737072000,"startTime":"0","endTime":"0","summary":"美国旧金山和中国苏州2025年1月17日 /美通社/ -- 信达生物制药集团，一家致力于研发、生产和销售肿瘤、自身免疫、代谢、眼科等重大疾病领域创新药物的生物制药公司，与奥赛康药业今日联合宣布，第三代表皮生长因子受体酪氨酸激酶抑制剂靶向药物奥壹新的新药上市申请获中国国家药品监督管理局批准上市，用于既往经EGFR-TKI治疗时或治疗后出现疾病进展，并且经检测确认存在EGFR T790M突变阳性的局部晚期或转移性非小细胞肺癌成人患者治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4598259_ZH98259_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4139","BK1589","IVBIY","LU2488822045.USD","01801","ORR","BK4195","PFS","PPI","BK1161","LU2328871848.SGD","BK4570","LU1969619763.USD","BK4211","BK1583"],"gpt_icon":0},{"id":"2503838069","title":"信达生物IBI343 (CLDN 18.2 ADC) 获国家药品监督管理局纳入突破性治疗药物品种，治疗晚期胰腺导管腺癌患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2503838069","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503838069?lang=zh_cn&edition=full","pubTime":"2025-01-16 08:01","pubTimestamp":1736985660,"startTime":"0","endTime":"0","summary":"目前，晚期胰腺癌的治疗主要依赖于系统性化疗。IBI343与表达CLDN18.2的肿瘤细胞结合后，发生CLDN18.2依赖性内化，随后可裂解的连接子降解，从而释放的药物引起DNA损伤，导致肿瘤细胞凋亡。截至目前，IBI343的两项适应症获中国国家药品监督管理局药品评审中心纳入突破性治疗药物品种名单，用于至少接受过二种系统性治疗的CLDN18.2表达阳性的晚期胃/胃食管交界处腺癌，及至少接受过一种系统性治疗的CLDN18.2表达阳性的晚期胰腺导管腺癌。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4596993_ZH96993_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU2488822045.USD","ADC","BK4139","BK4080","BK1161","BK4231","IVBIY","LU2328871848.SGD","LU1969619763.USD","BK1583","BK1589","01801"],"gpt_icon":0},{"id":"2501421763","title":"信达生物将出席第43届摩根大通全球医疗健康年会并发表演讲","url":"https://stock-news.laohu8.com/highlight/detail?id=2501421763","media":"美通社","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2501421763?lang=zh_cn&edition=full","pubTime":"2025-01-06 08:00","pubTimestamp":1736121600,"startTime":"0","endTime":"0","summary":"美国旧金山和中国苏州2025年1月6日 /美通社/ -- 信达生物制药集团，一家致力于研发、生产和销售肿瘤、自身免疫、代谢、眼科等重大疾病领域创新药物的生物制药公司宣布，公司管理层将出席在美国旧金山举办的第43届摩根大通医疗健康年会。摩根大通全球医疗健康年会是全球最负盛名、规模最大的医疗健康投资研讨会之一。截至目前，信达生物患者援助项目已惠及20余万普通患者，药物捐赠总价值36亿元人民币。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4589052_ZH89052_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU0882574139.USD","IE00B1XK9C88.USD","LU0070302665.USD","LU0251132253.USD","LU0170899867.USD","LU0976567544.SGD","LU0106831901.USD","IE00BDCRKT87.USD","IE00BLSP4452.SGD","LU1988902786.USD","IE00BKVL7J92.USD","LU0238689110.USD","LU2357305700.SGD","LU2264538146.SGD","LU2237443382.USD","LU1244550221.USD","LU2328871848.SGD","BK1589","LU1720051017.SGD","LU1244550577.SGD","LU1720051108.HKD","LU1668664300.SGD","LU2237443549.SGD","LU1119994496.HKD","LU0215105999.USD","LU2488822045.USD","LU2237443895.HKD","LU1244550494.USD","LU0211326839.USD","LU1670628061.USD","IE00BLSP4239.USD","BK4533","LU0234572021.USD","IE00BJTD4V19.USD","BK1161","LU0149725797.USD","IE0034235188.USD","LU2552382058.USD","IVBIY","IE00BJTD4N35.SGD","LU0683600562.USD","LU0320765489.SGD","BK4207","LU1162221912.USD","LU1894683264.USD","LU2237443622.USD","LU1496350502.SGD","01801","LU0971096721.USD","LU1032466523.USD"],"gpt_icon":0},{"id":"2500132045","title":"信达生物宣布ROS1抑制剂达伯乐®（己二酸他雷替尼胶囊）获批第二项适应症，用于全线治疗 ROS1 阳性肺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2500132045","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500132045?lang=zh_cn&edition=full","pubTime":"2025-01-03 08:00","pubTimestamp":1735862400,"startTime":"0","endTime":"0","summary":"美国旧金山和中国苏州2025年1月3日 /美通社/ -- 信达生物制药集团，一家致力于研发、生产和销售肿瘤、自身免疫、代谢、眼科等重大疾病领域创新药物的生物制药公司宣布，新一代 ROS1 酪氨酸激酶抑制剂达伯乐的第二项新药上市申请获中国国家药品监督管理局批准上市，用于ROS1阳性的局部晚期或转移性非小细胞肺癌成人患者的治疗。除此之外，他雷替尼还获得美国FDA授予的用于治疗 ROS1 阳性非小细胞肺癌的孤儿药认定和突破性疗法认定。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4587875_ZH87875_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["01801","BK1161","BK1583","BK4195","ODD","BK4139","LU1969619763.USD","IVBIY","BK1589","BK4007","NUVB","BK4183","PFS","LU2328871848.SGD","LU2488822045.USD","BK4211"],"gpt_icon":0},{"id":"2493470395","title":"信达生物宣布ROS1抑制剂达伯乐®（己二酸他雷替尼胶囊）获国家药品监督管理局批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2493470395","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493470395?lang=zh_cn&edition=full","pubTime":"2024-12-20 20:08","pubTimestamp":1734696480,"startTime":"0","endTime":"0","summary":"美国旧金山和中国苏州2024年12月20日 /美通社/ -- 信达生物制药集团，一家致力于研发、生产和销售肿瘤、自身免疫、代谢、眼科等重大疾病领域创新药物的生物制药公司宣布，新一代ROS1酪氨酸激酶抑制剂达伯乐的新药上市申请获中国国家药品监督管理局批准上市，用于经ROS1-TKI治疗后进展的ROS1阳性局部晚期或转移性非小细胞肺癌成人患者的治疗。截至目前，信达生物患者援助项目已惠及17余万普通患者，药物捐赠总价值34亿元人民币。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4584619_ZH84619_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1161","BK1589","ODD","LU1969619763.USD","BK4183","01801","LU2488822045.USD","NUVB","BK4007","BK1583","BK4139","LU2328871848.SGD","IVBIY"],"gpt_icon":0},{"id":"2491729653","title":"信达生物与礼来制药深化肿瘤领域合作，达成捷帕力®（匹妥布替尼片）中国大陆商业化协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2491729653","media":"美通社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491729653?lang=zh_cn&edition=full","pubTime":"2024-12-16 07:55","pubTimestamp":1734306900,"startTime":"0","endTime":"0","summary":"根据协议，信达生物拥有捷帕力在中国大陆的进口、销售、推广和分销权利，礼来将负责该产品在中国大陆的持续研发和上市后医学事务相关工作。此次合作将充分利用信达生物在血液肿瘤领域丰富的商业化经验及礼来医学团队在血液肿瘤领域丰富的开发经验和科学洞见。双方将强强联手，致力于造福更多中国大陆癌症患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4580201_ZH80201_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["SG9999015952.SGD","LU0943347566.SGD","LU0238689110.USD","LU0672654240.SGD","SG9999015945.SGD","LU1868836757.USD","LU1988902786.USD","IE00B1BXHZ80.USD","IE00B2B36J28.USD","IVBIY","BK1583","LU1917777945.USD","LLY","SG9999014898.SGD","LU2488822045.USD","LU0006306889.USD","LU0114720955.EUR","LU0109391861.USD","SG9999018857.SGD","LU0058720904.USD","LU2360106947.USD","LU1127390331.HKD","LU2361044949.HKD","LU2361044865.SGD","LU2602419157.SGD","SG9999017495.SGD","LU0823416689.USD","IE00BJLML261.HKD","LU1064131342.USD","SGXZ81514606.USD","LU0882574055.USD","01801","SG9999015986.USD","LU0097036916.USD","LU2237438978.USD","LU0094547139.USD","LU0471298694.HKD","LU2237443978.SGD","LU0203202063.USD","LU2063271972.USD","LU0256863902.USD","BK4588","LU2237443549.SGD","LU0471298777.SGD","BK4533","LU2361045086.USD","LU1035775433.USD","SG9999001176.SGD","LU0061475181.USD","LU1061106388.HKD"],"gpt_icon":1},{"id":"2490709174","title":"2024 ESMO Asia | 信达生物口头报告创新型抗CLDN18.2 ADC（IBI343）治疗晚期胰腺癌的I期临床研究数据更新","url":"https://stock-news.laohu8.com/highlight/detail?id=2490709174","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490709174?lang=zh_cn&edition=full","pubTime":"2024-12-09 08:00","pubTimestamp":1733702400,"startTime":"0","endTime":"0","summary":"在扩大样本量的CLDN18.2表达阳性的既往经治的胰腺癌晚期患者中，IBI343进一步展示出了令人鼓舞的早期疗效数据和良好的安全性。在中国，2022年胰腺癌新发病例达12万，死亡病例11万。未发生TEAE导致的死亡。希望IBI343的临床推动，能够为全球患者带来突破性的治疗。作为创新型TOPO1i型ADC，IBI343在临床I期研究中展现出可控的安全性和令人鼓舞的疗效性信号，目前正在胃癌和胰腺癌等瘤种上探索IBI343的治疗潜力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4573831_ZH73831_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["ADC","IVBIY","BK4231","LU2328871848.SGD","BK1589","BK1161","BK4080","LU1969619763.USD","BK1583","LU2488822045.USD","01801","BK4139"],"gpt_icon":0},{"id":"2486035641","title":"信达生物宣布信必乐®（托莱西单抗注射液）新药、耐立克®（奥雷巴替尼）新增适应症成功纳入2024年版国家医保药品目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2486035641","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486035641?lang=zh_cn&edition=full","pubTime":"2024-11-28 12:05","pubTimestamp":1732766700,"startTime":"0","endTime":"0","summary":"新版国家医保目录将于2025年1月1日起正式实施。此次，信必乐新药纳入国家医保目录，用于治疗原发性高胆固醇血症和混合型血脂异常的成人患者。同时，耐立克新增适应症纳入国家医保目录，将使得更广泛的CML患者获益。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4567879_ZH67879_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1161","BK1589","IVBIY","01801","LU2488822045.USD","LU1969619763.USD","LU2328871848.SGD","BK1583","BK4139","CVM"],"gpt_icon":0},{"id":"2486725493","title":"信达生物将在ESMO Asia 2024年会上公布IBI343（CLDN18.2 ADC）等多项创新管线更新临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2486725493","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486725493?lang=zh_cn&edition=full","pubTime":"2024-11-25 08:16","pubTimestamp":1732493760,"startTime":"0","endTime":"0","summary":"美国旧金山和中国苏州2024年11月25日 /美通社/ -- 信达生物制药集团，一家致力于研发、生产和销售肿瘤、自身免疫、代谢及心血管、眼科等重大疾病领域创新药物的生物制药公司，今日宣布，将在2024年欧洲肿瘤内科学会亚洲年会上公布近10项临床数据，含2项口头报告，其中包括IBI343治疗胰腺癌的I期更新数据。ESMO Asia年会将于当地时间2024年12月6日-8日在新加坡举办。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4564278_ZH64278_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1161","BK1589","BK4231","IVBIY","01801","LU2488822045.USD","LU1969619763.USD","LU2328871848.SGD","BK1583","BK4080","ADC","BK4139"],"gpt_icon":0},{"id":"2476251188","title":"信达生物宣布匹康奇拜单抗（IL-23p19抗体）治疗溃疡性结肠炎的II期临床研究达成主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2476251188","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2476251188?lang=zh_cn&edition=full","pubTime":"2024-10-17 08:00","pubTimestamp":1729123200,"startTime":"0","endTime":"0","summary":"我很高兴看到匹康奇拜单抗治疗中重度活动性溃疡性结肠II期临床研究中达成主要终点，受试者获得显著的诱导期临床获益，同时安全性良好。近年来，以IL-23为靶点的新一代药物因其在溃疡性结肠炎患者治疗中卓越的疗效和良好的安全性引发关注；目前，国内市场上尚无IL-23p19靶点药物获批治疗溃疡性结肠炎，本研究是第一个由国内企业自主研发的IL-23p19单抗治疗溃疡性结肠炎的临床研究。溃疡性结肠炎严重威胁身体健康并对日常生活和心理带来影响。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4532408_ZH32408_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1583","LU1969619763.USD","01801","LU2328871848.SGD","IBD","BK4139","LU2488822045.USD","IVBIY","BK1161","BK1589"],"gpt_icon":0},{"id":"2473459176","title":"信达生物与奥赛康药业达成第三代EGFR TKI 肺癌靶向药物利厄替尼片（奥壹新®）的战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2473459176","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2473459176?lang=zh_cn&edition=full","pubTime":"2024-10-08 08:00","pubTimestamp":1728345600,"startTime":"0","endTime":"0","summary":"利厄替尼是具有自主知识产权、全新分子实体、活性显著的口服的第三代EGFR-TKI。我们与奥赛康在利厄替尼片（奥壹新）的合作有望给广大的EGFR突变肺癌患者提供一个创新靶向药物，同时这将进一步提升信达生物在肿瘤治疗领域的领先地位。2024年10月，信达生物与奥赛康就利厄替尼片在中国达成独家商业化合作。截至目前，信达生物患者援助项目已惠及17余万普通患者，药物捐赠总价值34亿元人民币。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4518499_ZH18499_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1161","BK1583","BK4195","BK4570","PFS","IVBIY","CNS","01801","BK4135","LU2488822045.USD","BK4139","PPI","LU1969619763.USD","BK4211","BK1589","LU2328871848.SGD"],"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"ytd","weight":0}],"exchange":"PINK LIMITED","name":"Innovent Biologics Inc.","nameEN":"Innovent Biologics Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Innovent Biologics Inc.(IVBIY)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Innovent Biologics Inc.(IVBIY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Innovent Biologics Inc.,IVBIY,Innovent Biologics Inc.股票,Innovent Biologics Inc.股票老虎,Innovent Biologics Inc.股票老虎国际,Innovent Biologics Inc.行情,Innovent Biologics Inc.股票行情,Innovent Biologics Inc.股价,Innovent Biologics Inc.股市,Innovent Biologics Inc.股票价格,Innovent Biologics Inc.股票交易,Innovent Biologics Inc.股票购买,Innovent Biologics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Innovent Biologics Inc.(IVBIY)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Innovent Biologics Inc.(IVBIY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}